Experience With an Electronic Brachytherapy Technique for Intracavitary Accelerated Partial Breast Irradiation

Mehta, Vivek; Algan, Özer; Griem, Katherine L.; Dickler, Adam; Haile, Kenneth; Wazer, David E.; Stevens, Ryan W; Chadha, Manjeet; Kurtzman, Steve; Modin, Sheela D.; Dowlatshahi, Kambiz; Elliott, Kelly W.; Rusch, Thomas W.

doi:10.1097/coc.0b013e3181d79d9e

Cited by 24 publications

(46 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When using a balloon approach, the implant is positioned after BCS procedure and serves to define the treatment volume. For treatment, the balloon cavity is loaded with an Iridium-192 source or an electronic X-ray generator, which delivers the prescribed dose and subsequently is removed (Dooley et al 2011;Mehta et al 2010;Mille et al 2010). Overall, the technique may reduce exposure to radiation healthy tissue and body organs, such as the heart and lungs (Dickler et al 2007;Milele et al 2009).…”

Section: Intralesionalmentioning

confidence: 98%

Experimental Therapies in Breast Cancer

Rabatic

2014

Medical Radiology

View full text Add to dashboard Cite

Section: Intralesionalmentioning

confidence: 98%

Experimental Therapies in Breast Cancer

Rabatic

2014

Medical Radiology

View full text Add to dashboard Cite

“…Source strength is verified using an internal well chamber before each treatment. Balloon catheters have been used to treat early stage breast cancer, initially with multiple fractions 24 and then with single fraction IORT, as described below. Dose distributions are similar to the MammoSite® balloon catheter (Cytec Industries Inc., Mountain View, CA) used with iridium-192 ( 192 Ir) HDR sources, but with higher doses close to the applicator surface, which may increase the risk of fat necrosis.…”

Section: Clinical Systemsmentioning

confidence: 99%

Electronic brachytherapy—current status and future directions

Eaton¹

2015

BJR

View full text Add to dashboard Cite

In the past decade, electronic brachytherapy (EB) has emerged as an attractive modality for the treatment of skin lesions and intraoperative partial breast irradiation, as well as finding wider applications in intracavitary and interstitial sites. These miniature X-ray sources, which operate at low kilovoltage energies (,100 kV), have reduced shielding requirements and inherent portability, therefore can be used outside the traditional realms of the radiotherapy department. However, steep dose gradients and increased sensitivity to inhomogeneities challenge accurate dosimetry. Secondly, ease of use does not mitigate the need for close involvement by medical physics experts and consultant oncologists. Finally, further studies are needed to relate the more heterogeneous dose distributions to clinical outcomes. With these provisos, the practical convenience of EB strongly suggests that it will become an established option for selected patients, not only in radiotherapy departments but also in a range of operating theatres and clinics around the world.

show abstract

“…In MEBXS skin cancer treatment at different anatomical sites (i.e. scalp, forearm, and legs), (Rong and Welsh, 2010;Bhatnagar, 2013) and/or Accelerated Partial Breast Irradiation (APBI) (Mehta et al, 2010) the bone heterogeneities are significant, and bone heterogeneity effect is not exactly considered for this type of brachytherapy, however TG-43U1 dosimetric of the MEBXS in water phantom, published by some groups (Rivard et al, 2006;Safigholi et al, 2012). The aim of this work is to characterize the sensitivity to heterogeneities cause by various bone thicknesses on the TG-43U1 radial dose functions for MEBXS in a spherical phantom.…”

Section: Introductionmentioning

confidence: 99%